Skip to content

Released Nov 5, 2026, before the open

10-Q filed Nov 5, 2026, 36 days after period end · 0001193125-26-448543

Q3 2026 · 10-Q
Revenue$0.00−100.0% vs Q3 2025−100.0% vs Q2 2026
Net Income-$30.69MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.25N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$32,247,000N/M
Operating Cash Flow-$27,800,000N/M
Free Cash Flowderived-$27,893,000N/M

What the release said

The California Institute for Regenerative Medicine (CIRM) awarded the Company a $15.0 million grant through its CLIN2 program to support the clinical development of RECLAIM-LN.

Fate Therapeutics reported a net loss of $30.7 million, or $(0.25) per share, for the third quarter of 2026, compared with $32.3 million, or $(0.27) per share, for the third quarter of 2025.2

Cash, cash equivalents, and investments were $139.1 million as of September 30, 2026, a quarterly decrease of $14.7 million, and the company said this extends its cash runway to mid-2028 with the new grant.34

The California Institute for Regenerative Medicine awarded the company a $15.0 million CLIN2 grant to support the clinical development of RECLAIM-LN.1

Across 29 autoimmune patients treated with a single dose of FT819 as of an August 18, 2026 data cutoff, Grade 1–2 cytokine release syndrome occurred in 5 patients (17.2%).56

Net loss, third quarter 2026
$30.7 million Compared with $32.3 million for the third quarter of 20252
Net loss per share, third quarter 2026
$(0.25) Compared with $(0.27) per share for the third quarter of 20252
Cash, cash equivalents, and investments
$139.1 million As of September 30, 2026; a quarterly decrease of $14.7 million3
Total operating expenses
$32.2 million For the third quarter of 20267
CIRM CLIN2 grant
$15.0 million Awarded to support RECLAIM-LN1
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$0.00$1.74M$3.07M$1.94M
Net Income-$30.69M-$32.25M-$47.68M-$45.17M
EPS Diluted-$0.25-$0.27-$0.40-$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR